Avichai Shimoni

Research interests

Publications

• Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

  Leukemia · 2022 · 10.1038/s41375-022-01739-2

• External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation

  Blood Advances · 2019 · 10.1182/bloodadvances.2019032268

• Early and late hematologic toxicity following CD19 CAR-T cells

  Bone Marrow Transplantation · 2019 · 10.1038/s41409-019-0487-3

• Second Malignancies after Hematopoietic Stem Cell Transplantation

  Current Treatment Options in Oncology · 2018 · 10.1007/s11864-018-0528-y

• Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.59.1339

• Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT

  Bone Marrow Transplantation · 2013 · 10.1038/bmt.2013.146

• Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

  Clinical Cancer Research · 2013 · 10.1158/1078-0432.ccr-13-0380

• The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

  Clinical Cancer Research · 2013 · 10.1158/1078-0432.ccr-13-1302

• Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen—A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2013.48.8114

• Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

  PubMed · 2013

• A randomized study comparing yttrium‐90 ibritumomab tiuxetan (Zevalin) and high‐dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma

  Cancer · 2012 · 10.1002/cncr.27418

• Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike

  Bone Marrow Transplantation · 2011 · 10.1038/bmt.2011.88

• Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

  Clinical Cancer Research · 2010 · 10.1158/1078-0432.ccr-10-0041

• Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients

  Journal of Immunotherapy · 2009 · 10.1097/cji.0b013e31819c8bda

• Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma

  Annals of Oncology · 2009 · 10.1093/annonc/mdp271

• Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

  Clinical Cancer Research · 2008 · 10.1158/1078-0432.ccr-07-4079

• Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan

  Leukemia · 2007 · 10.1038/sj.leu.2404886

• Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)

  Bone Marrow Transplantation · 2006 · 10.1038/sj.bmt.1705259

• Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

  British Journal of Haematology · 2005 · 10.1111/j.1365-2141.2005.05513.x

• Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

  Leukemia · 2005 · 10.1038/sj.leu.2404037

• Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)

  Leukemia · 2005 · https://doi.org/10.1038/sj.leu.2403967

• Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

  Leukemia · 2004 · 10.1038/sj.leu.2403591

• Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

  Transplantation and Cellular Therapy · 2004 · 10.1016/j.bbmt.2004.06.002

• Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma

  Blood · 2004 · 10.1182/blood-2004-05-2031

• Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

  British Journal of Haematology · 2000 · 10.1046/j.1365-2141.2000.02196.x

Current projects

No projects listed.